Therapy assessment of bone metastatic disease in the era of 223radium.
about
Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.Uptake of Radium-223 Dichloride and Early [(18)F]NaF PET Response Are Driven by Baseline [(18)F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients.The Potential Use of 11C-Choline Positron Emission Tomography/Computed Tomography to Monitor the Treatment Effects of Radium-223 in a Patient with Prostate Cancer
P2860
Therapy assessment of bone metastatic disease in the era of 223radium.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Therapy assessment of bone metastatic disease in the era of 223radium.
@en
Therapy assessment of bone metastatic disease in the era of 223radium.
@nl
type
label
Therapy assessment of bone metastatic disease in the era of 223radium.
@en
Therapy assessment of bone metastatic disease in the era of 223radium.
@nl
prefLabel
Therapy assessment of bone metastatic disease in the era of 223radium.
@en
Therapy assessment of bone metastatic disease in the era of 223radium.
@nl
P2093
P2860
P1476
Therapy assessment of bone metastatic disease in the era of 223radium
@en
P2093
Alireza Rezaee
Ana Emilia Brito
Werner Langsteger
P2860
P2888
P356
10.1007/S00259-017-3734-0
P433
P577
2017-05-31T00:00:00Z